Lihong Yao1, Haijin Zhao1, Haixiong Tang1, Junjie Liang1, Laiyu Liu1, Hangming Dong1, Fei Zou2, Shaoxi Cai1. 1. Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China. 2. School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China.
Abstract
BACKGROUND AND PURPOSE: Cytoplasmic retention of β-catenin will lead to its nuclear translocation and subsequent interaction with the transcription factor TCF/LEF that regulates target gene expression. We have previously demonstrated aberrant expression of β-catenin in a model of asthma induced by toluene diisocyanate (TDI). The aim of this study was to examine whether the receptor for advanced glycation end products (RAGE) can regulate β-catenin expression in TDI-induced asthma. EXPERIMENTAL APPROACH: Male BALB/c mice were sensitized and challenged with TDI to generate a chemically-induced asthma model. Inhibitors of RAGE, FPS-ZM1 and the RAGE antagonist peptide (RAP), were injected i.p. after each challenge. Airway resistance was measured in vivo and bronchoalveolar lavage fluid was analysed. Lungs were examined by histology and immunohistochemistry. Western blotting and quantitative PCR were also used. KEY RESULTS: Expression of RAGE and of its ligands HMGB1, S100A12, S100B, HSP70 was increased in TDI-exposed lungs. These increases were inhibited by FPS-ZM1 or RAP. Either antagonist blunted airway reactivity, airway inflammation and goblet cell metaplasia, and decreased release of Th2 cytokines. TDI exposure decreased level of membrane β-catenin, phosphorylated Akt (Ser(473) ), inactivated GSK3β (Ser(9) ), dephosphorylated β-catenin at Ser(33) /(37) /Thr(41) , which controls its cytoplasmic degradation, increased phosphorylated β-catenin at Ser(552) , raised cytoplasmic and nuclear levels of β-catenin and up-regulated its targeted gene expression (MMP2, MMP7, MMP9, VEGF, cyclin D1, fibronectin), all of which were reversed by RAGE inhibition. CONCLUSION AND IMPLICATIONS: RAGE was required for stabilization of β-catenin in TDI-induced asthma, identifying protective effects of RAGE blockade in this model.
BACKGROUND AND PURPOSE: Cytoplasmic retention of β-catenin will lead to its nuclear translocation and subsequent interaction with the transcription factor TCF/LEF that regulates target gene expression. We have previously demonstrated aberrant expression of β-catenin in a model of asthma induced by toluene diisocyanate (TDI). The aim of this study was to examine whether the receptor for advanced glycation end products (RAGE) can regulate β-catenin expression in TDI-induced asthma. EXPERIMENTAL APPROACH: Male BALB/c mice were sensitized and challenged with TDI to generate a chemically-induced asthma model. Inhibitors of RAGE, FPS-ZM1 and the RAGE antagonist peptide (RAP), were injected i.p. after each challenge. Airway resistance was measured in vivo and bronchoalveolar lavage fluid was analysed. Lungs were examined by histology and immunohistochemistry. Western blotting and quantitative PCR were also used. KEY RESULTS: Expression of RAGE and of its ligands HMGB1, S100A12, S100B, HSP70 was increased in TDI-exposed lungs. These increases were inhibited by FPS-ZM1 or RAP. Either antagonist blunted airway reactivity, airway inflammation and goblet cell metaplasia, and decreased release of Th2 cytokines. TDI exposure decreased level of membrane β-catenin, phosphorylated Akt (Ser(473) ), inactivated GSK3β (Ser(9) ), dephosphorylated β-catenin at Ser(33) /(37) /Thr(41) , which controls its cytoplasmic degradation, increased phosphorylated β-catenin at Ser(552) , raised cytoplasmic and nuclear levels of β-catenin and up-regulated its targeted gene expression (MMP2, MMP7, MMP9, VEGF, cyclin D1, fibronectin), all of which were reversed by RAGE inhibition. CONCLUSION AND IMPLICATIONS: RAGE was required for stabilization of β-catenin in TDI-induced asthma, identifying protective effects of RAGE blockade in this model.
Authors: Stijn P De Langhe; Frédéric G Sala; Pierre-Marie Del Moral; Timothy J Fairbanks; Kenneth M Yamada; David Warburton; Robert C Burns; Saverio Bellusci Journal: Dev Biol Date: 2005-01-15 Impact factor: 3.582
Authors: Martijn C Nawijn; Tillie L Hackett; Dirkje S Postma; Antoon J M van Oosterhout; Irene H Heijink Journal: Trends Immunol Date: 2011-04-12 Impact factor: 16.687
Authors: Maria B Sukkar; Md Ashik Ullah; Wan Jun Gan; Peter A B Wark; Kian Fan Chung; J Margaret Hughes; Carol L Armour; Simon Phipps Journal: Br J Pharmacol Date: 2012-11 Impact factor: 8.739
Authors: Ethan David Cohen; Kaori Ihida-Stansbury; Min Min Lu; Reynold A Panettieri; Peter Lloyd Jones; Edward E Morrisey Journal: J Clin Invest Date: 2009-08-17 Impact factor: 14.808
Authors: Ioannis Gkouveris; Danny Hadaya; Naseim Elzakra; Akrivoula Soundia; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Tara Aghaloo; Sotirios Tetradis Journal: J Bone Miner Res Date: 2022-07-11 Impact factor: 6.390
Authors: Jing Xiong; Wen-Qu Zhao; Guo-Hua Huang; Li-Hong Yao; Hang-Ming Dong; Chang-Hui Yu; Hai-Jin Zhao; Shao-Xi Cai Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2017-10-20
Authors: Alexandre Carvalho; Jacky Lu; Jamisha D Francis; Rebecca E Moore; Kathryn P Haley; Ryan S Doster; Steven D Townsend; Jeremiah G Johnson; Steven M Damo; Jennifer A Gaddy Journal: Gastroenterol Res Pract Date: 2020-02-26 Impact factor: 2.260